| Literature DB >> 35783363 |
Alejandro Hernández Solís1, Javier Araiza Santibáñez2, Jazmín Guadalupe Tejeda Olán2, Andrea Quintana Martínez1, Alejandro Hernández de la Torriente3, Rocio de la Torriente Mata4.
Abstract
Pulmonary histoplasmosis is caused by inhaling Histoplasma capsulatum. Less than 1% develops the disease. Risk factors in immunocompetent individuals are environmental exposures in endemic areas. The objective of this study is to determine the frequency, clinical, and microbiological characteristics in immunocompetent patients. A retrospective case series study of patients diagnosed with pulmonary histoplasmosis was performed in a respiratory care unit in Mexico City from 2000 to 2020. Each patient had bronchial lavage, and three patients underwent thoracoscopy for the lung tissue sample taken for the culture in Sabouraud Dextrose Agar. Twelve patients were identified, 8 males and 4 females; the predominant symptoms were fever (83%), dyspnea (75%), chest pain (66%), hemoptysis (41%), and weight loss (33%). The computed tomography of the chest showed the following findings: patchy consolidation 12 (100%), hilar adenopathy 6 (50%), pleural effusion 6 (50%), caverns 3 (25%), and solitary pulmonary nodule in one patient (8%). Histoplasma capsulatum was found in the culture of all twelve patients. The signs and symptoms of the disease are mediated by the immune status of the host. The clinical picture is often confused with systemic diseases. It is important to have a high degree of clinical suspicion to make a timely diagnosis.Entities:
Year: 2022 PMID: 35783363 PMCID: PMC9249480 DOI: 10.1155/2022/2121714
Source DB: PubMed Journal: Can J Infect Dis Med Microbiol ISSN: 1712-9532 Impact factor: 2.585
Figure 1Necrotizing pneumonia due to Histoplasma capsulatum. (a) Chest X-ray (PA), with the presence of heterogeneous consolidation with radio lucid areas inside. (b, c) Chest CT showing lobar consolidation, cavitation in the right upper lobe, and parahilar lymphadenopathy.
Patients with acute histoplasmosis.
| Age/gender | Risk factors | Days onset | Symptoms | Imaging CT | Diagnosis | Treatment | Follow-up |
|---|---|---|---|---|---|---|---|
| 42male | Practice | 18 | Fever, dyspnea, chest pain | Consolidation, pleural effusion, HA | Bronchoalveolar lavage, histoplasmin + | Itraconazole for 12 weeks | 1 year |
| 38female | Endemic area | 10 | Fever, chest pain | Consolidation, pleural effusion | Bronchoalveolar lavage, histoplasmin + | Itraconazole for 6 weeks | 6 months |
| 56male | Smoking, endemic area | 6 | Fever, dyspnea, hemoptysis, weight loss | Consolidation, solitary pulmonary nodule, HA | Bronchoalveolar lavage and thoracoscopy biopsy | AmB, methylprednisolone | Died |
| 51female | Wood smoke | 5 | Fever, dyspnea, chest pain | Consolidation, pleural effusion | Bronchoalveolar lavage | Itraconazole for 12 weeks | 1 year |
| 55male | Smoking | 8 | Dyspnea, hemoptysis, chest pain | Consolidation, pleural effusion | Histoplasmin +, bronchoalveolar lavage | AmB for 2 weeks followed by itraconazole for 10 weeks methylprednisolone | 1 year |
| 49female | Endemic area | 11 | Fever, hemoptysis | Consolidation, hilar adenopathy | Histoplasmin +, bronchoalveolar lavage | Itraconazole for 6 weeks | 6 months |
| 40male | Practice speleology, endemic area | 7 | Fever, dyspnea, chest pain | Consolidation, pleural effusion | Histoplasmin +, bronchoalveolar lavage | Itraconazole for 12 weeks | 1 year |
| 50female | None | 13 | Fever, dyspnea, chest pain | Consolidation, pleural effusion, HA | Histoplasmin +, bronchoalveolar lavage | Itraconazole for 6 weeks | 6 months |
| 47male | Practice speleology, endemic area | 4 | Fever, chest pain, weight loss | Consolidation, pleural effusion | Histoplasmin +, bronchoalveolar lavage | Itraconazole for 12 weeks | 1 year |
| 41male | Practice speleology, endemic area | 29 | Dyspnea, hemoptysis, weight loss | Consolidation, cavern, HA | Bronchoalveolar lavage and thoracoscopy biopsy | AmB | Died |
HA : Hilar adenopathy; AmB: amphotericin B.
Figure 2(a) Multiple nodular, hemorrhagic, and cavitated lesions scattered throughout the lung parenchyma. (b) Sabouraud's dextrose agar medium observing white, downy-looking colonies. (c) Direct examination with lactophenol cotton blue, in which thin, septate, hyaline hyphae with round, spiculated macroconidia were observed in a 40X image.
Patients with chronic histoplasmosis.
| Patients | Risk factors | Days onset | Symptoms | Imaging CT | Diagnosis | Treatment | Follow-up |
|---|---|---|---|---|---|---|---|
| 55male | Smoking | 6 months | Fever, dyspnea, weight loss | Consolidation, cavern | Thoracoscopy biopsy and bronchoalveolar lavage | Itraconazole for 12 months | 1 year |
| 57male | Endemic area | 4 months | Fever, dyspnea, hemoptysis, chest pain | Consolidation, cavern, HA | Histoplasmin +, bronchoalveolar lavage | Itraconazole | Died |
HA : Hilar adenopathy.
Characteristics presented in immunocompetent patients with pulmonary histoplasmosis.
| Characteristics |
| (%) |
|---|---|---|
| Patients | ||
| Male | 8 | (66%) |
| Female | 4 | (33%) |
|
| ||
| Symptoms | ||
| Fever | 10 | (83%) |
| Dyspnea | 9 | (75%) |
| Chest pain | 8 | (66%) |
| Hemoptysis | 5 | (41%) |
| Weight loss | 4 | (33%) |
|
| ||
| Findings | ||
| Lymphadenopathy | 7 | (58%) |
| Hepatomegaly | 5 | (41%) |
| Splenomegaly | 2 | (16%) |
|
| ||
| Laboratory findings | ||
| Neutropenia | 5 | (41%) |
| Moderate | 3 | (25%) |
| Severe | 2 | (16%) |
| Abnormal liver function tests | 5 | (41%) |
|
| ||
| Chest imaging | ||
| Consolidation | 12 | (100%) |
| Hilar adenopathy | 6 | (50%) |
| Pleural effusion | 6 | (50%) |
| Caverns | 3 | (25%) |
| Solitary pulmonary nodule | 1 | (8%) |
|
| ||
| Mortality | ||
| Dead | 3 | (25%) |